Related Experiment Video
Updated: Aug 28, 2026
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study
Ahmet Omma1, Abdulsamet Erden1, Serdar Can Güven1
1Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
Insights
Convalescent plasma (CP) treatment for COVID-19 patients may reduce long-term antibody levels. This study found lower antibody titers in CP recipients compared to a control group, suggesting potential impacts on immunity.
Area of Science:
- Immunology
- Infectious Diseases
- Hematology
Background:
- COVID-19 treatment strategies are evolving.
- Convalescent plasma (CP) has been explored as a therapeutic option.
- Understanding the long-term immunological effects of CP is crucial.
Purpose of the Study:
- To investigate post-COVID-19 antibody titers in patients treated with convalescent plasma (CP).
- To compare antibody levels between COVID-19 patients receiving CP and those receiving standard care.
Main Methods:
- Retrospective analysis of hospitalized COVID-19 patients.
- Inclusion of patients with recorded total COVID-19 antibody test results post-treatment.
- Formation of a control group matched for age, gender, and comorbidities.
- Comparison of total COVID-19 antibody index levels between CP recipients and the control group.
Main Results:
- The study included 33 CP recipients and 34 matched controls.
- Median total COVID-19 antibody index levels were significantly reduced in the CP group.
- This indicates a potential suppression of antibody response following CP therapy.
Conclusions:
- Convalescent plasma therapy may offer benefits for acute COVID-19 disease outcomes.
- However, CP treatment might potentially impair the development of long-term immunity.
- Further research is needed to fully understand the implications for sustained immune protection.
Objective:
The aim of this study is to investigate post-COVID-19 antibody titers in patients who received convalescent plasma (CP) in addition to standard-of-care treatment.
Materials And Methods:
Hospitalized COVID-19 patients who received CP in addition to standard care were retrospectively investigated. Patients who received CP with a recorded total COVID-19 antibody test result after treatment were included. From among hospitalized COVID-19 patients who received only standard care with a recorded total COVID-19 antibody test result, a control group matched for age, gender, and comorbidities was formed. Total COVID-19 antibody index levels were compared.
Results:
Thirty-three CP recipients were enrolled in the study. The control group consisted of 34 age-, gender-, and comorbidity-matched standard-care patients. Median total COVID-19 antibody index levels were significantly reduced in the CP group.
Conclusion:
Although CP therapy may have benefits for disease outcome, its potential ability to hamper long-term immunity may be a problem.
